Partner with Caris
In Depth Molecular Intelligence for Biophama
Precision Medicine Starts with Molecular Profiling of Every Gene
The fundamental understanding of disease at the molecular level is the essence of precision medicine. Because almost every gene may be implicated in cancer, we profile every patient’s DNA, RNA through whole exsome and whole transcriptome sequencing, plus added protein analysis and whole slide imaging. Caris has built the molecular profiling platforms and data solutions to unravel the molecular complexities of disease and is uniquely positioned to accelerate novel therapy development and interventions.
- Profiling
- MI Insights™
- Clinical Trials
- Companion Diagnostics
We go deeper farther and capture more data with our precise molecular testing. MI Cancer Seek is clinically and analytically validated demonstrating 97% positive and negative agreement and published in peer reviewed journals1 .With industry-leading, comprehensive molecular tissue profiling that encompasses unprecedented whole exome and whole transcriptome sequencing Caris provides actionable insights to inform your precision medicine programs.
Molecular Profiling
Unlock Actionable Insights
The Caris molecular profiling approach is widely recognized as the most comprehensive and clinically relevant tumor profiling portfolio on the market. For tissue-based profiling, Caris analyzes DNA and RNA (23,000+ gene coverage via WES and WTS), plus proteins, as well as leverages proprietary molecular AI-based signatures across all solid tumors.
Analyze 23,000 genes through whole exome (WES-DNA), whole transcriptome sequencing (WTS-RNA), plus Immunohistochemistry (IHC-proteins) and H&E slides.
Clinical Trials Powered by Data
Caris’ patient-matched molecular and clinical data can help find the answers to the most challenging clinical questions. With massive, integrated data covering single gene biomarkers, complex genome-wide signatures, fusions, IHC and H&E slide data, Caris enables biopharma partners to gain insights into patient cohorts and clinical outcomes throughout the patient journey, providing multiple pathways for success. Caris maintains a very large tissue bank with molecularly characterized samples across many tumor types. This is especially valuable for rare biomarkers, pan-tumor biomarkers, multi-variant biomarkers, and complex analytical validation studies. Importantly, these samples are available onsite at Caris, which significantly streamlines research studies and reduces operational burden and timeline risk for Biopharma partners.
Innovative Commercialization Resources for Biopharma
- Tissue agnostic CDx and tumor profiling claims support use for solid tumor indications
- Feasibility and development, analytical, and clinical validation solutions
- Strong global clinical and regulatory support in U.S. and ex-U.S. IVD markets
1 Ghani H, Helmstetter A, Ribeiro JR, Maney T, Rock S, Feldman RA, Swensen J, Abdulla F, Spetzler DB, Florento E, Vanderwalde AM, Pittman P, Radovich M, Hechtman J, Bales C, Sledge GW, George MM, Bryant D, Abraham JP, Oberley MJ. GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling. Cancer Res Commun. 2025 Sep 1;5(9):1477-1489. doi: 10.1158/2767-9764.CRC-25-0171. PMID: 40741943; PMCID: PMC12399951.
Discover
More
Caris Life Sciences is at the forefront of a data-led revolution in personalized cancer care. In partnership with biopharma innovators, Caris is shaping the future of precision oncology by developing groundbreaking solutions that deliver powerful outcomes.
Despite transformational breakthroughs in our understanding of disease, drug development has focused on a redundant, limited number of targets.